Applied Molecular Transport oral ulcerative colitis candidate fails in mid-stage trial
Applied Molecular Transport oral ulcerative colitis candidate fails in mid-stage trial
317
views
AMT-101, an oral candidate for ulcerative colitis from Applied Molecular Transport (AMTI), has failed in a phase 2 trial.
Applied Molecular Transport oral ulcerative colitis candidate fails in mid-stage trialDec. 22, 2022 6:19 PM ETApplied Molecular Transport Inc. (AMTI)By: Jonathan Block, SA News Editor

Scientist holding medical samples in laboratory

FangXiaNuo/E+ via Getty Images

Comments

https://stocktradingwebsites.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!